FTRE - NASDAQ
Fortrea Holdings Inc.
$15.63
+1.8%Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
At a Glance
Live Snapshotftre
Total Non-Current Assets
Last Annual Value
1.82B
3-Year CAGR
-16%
5-Year CAGR
-11%
10-Year CAGR
-6%
Fortrea Holdings Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Fortrea Holdings Inc. NASDAQ:FTRE | 1.82B | -16.1% | -11.0% | N/A | |
 ProKidney Corp. NASDAQ:PROK | 54.90M | 5.8% | 33.3% | N/A | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 474.33M | -15.5% | -16.6% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 35.34M | 50.4% | 6.6% | 35.8% | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 488.74M | 13.9% | 4.5% | N/A | |
 AnaptysBio, Inc. NASDAQ:ANAB | 14.14M | -32.3% | -30.8% | 13.5% | |
 Xencor, Inc. NASDAQ:XNCR | 275.67M | -5.8% | -7.8% | -0.4% | |
 Kura Oncology, Inc. NASDAQ:KURA | 29.70M | 21.8% | 20.4% | 40.2% | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 272.00K | -55.7% | 25.6% | N/A | |
 Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | 30.18M | 22.5% | 59.7% | N/A | |
 BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | 22.92M | 309.9% | 175.6% | N/A |
Fortrea Holdings Inc. Fair Value Envelope
Related Guides
Continue your FTRE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.